The Egyptian Drug Authority held high-level talks with a Takeda Pharmaceutical delegation to expand scientific research collaboration and improve patient access to innovative treatments. Discussions covered advancing ongoing projects and exploring new areas aligned with Egypt's national healthcare strategy.
The Egyptian Drug Authority (EDA) held high-level talks with a senior delegation from Takeda Pharmaceutical, led by Khaled Sary, attended by Ali El-Ghamrawy, EDA Chairperson. The meeting focused on expanding collaboration in scientific research and enhancing Egyptian patients' access to innovative treatments, as part of Egypt's strategy to bolster its healthcare sector and pharmaceutical system. Participants reviewed regulatory initiatives to improve medicine availability, especially in priority therapeutic areas. Takeda representatives outlined recent developments in their clinical trial activities and research efforts in the Egyptian market, stressing the need for ongoing coordination with the EDA to build research capabilities. The delegation was briefed on the Authority's future plans to strengthen intellectual property protection for pharmaceutical products, aiming to improve the investment climate and align Egypt with international standards. El-Ghamrawy emphasized the EDA's commitment to supporting research initiatives and expanding the clinical trials framework, stating these efforts are essential to position Egypt as a regional hub for pharmaceutical R&D. He expressed eagerness to partner with global companies for expertise exchange and drug innovation benefiting patients. Takeda officials expressed appreciation for the constructive partnership with the EDA, praising its role in strengthening the national pharmaceutical landscape. They reaffirmed plans to expand operations in Egypt, particularly in research, development, and clinical trials, to accelerate innovation and broaden access to advanced therapies. This meeting is part of the EDA's ongoing efforts to forge strategic ties with international pharmaceutical firms.